And the other researchers also suggested that expression of ERBB-2 is much lower on MB tumor cells than on breast cancer cells, so they are not susceptible to ERBB-2 monoclonal antibodies, like trastuzumab (Herceptin) [5]. The gene discussed is ERBB2; the disease is breast cancer.